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Abstract
Background: New technologies have enabled genome-wide association studies to be conducted
with hundreds of thousands of genotyped SNPs. Several different first-generation genome-wide
panels of SNPs have been commercialized. The total amount of common genetic variation is still
unknown; however, the coverage of commercial panels can be evaluated against reference
population samples genotyped by the International HapMap project. Less information is available
about coverage in samples from other populations.
Results: In this study we compare four commercial panels: the HumanHap 300 and HumanHap
550 Array Sets from the Illumina Infinium series and the Mapping 100 K and Mapping 500 K Array
Sets from the Affymetrix GeneChip series. Tagging performance is compared among HapMap
CEPH (CEU), Asian (JPT, CHB) and Yoruba (YRI) population samples. It is also evaluated in an
Estonian population sample with more than 1000 individuals genotyped in two 500-kbp ENCODE
regions of chromosome 2: ENr112 on 2p16.3 and ENr131 on 2p37.1.
Conclusion: We found that in a non-reference Caucasian population, commercial SNP panels
provide levels of coverage similar to those in the HapMap CEPH population sample. We present
the proportions of universal and population-specific SNPs in all the commercial platforms studied.
Background
Reduced genotyping costs and the availability of the Inter-
national HapMap Project data [1] have made genome-
wide association studies possible [2,3]. Multiple commer-
cial SNP panels have been made available for large-scale
studies. As the SNP selection strategies of these panels are
different [4], it is important to know how well they can
capture common variations in the human genome. Sev-
eral studies have evaluated the "completeness" of these
commercial panels on the HapMap population data [4-6].
The results of these studies indicate that most common
SNPs are well captured, and despite substantial differ-
ences in marker selection strategies, the first-generation
high-throughput platforms all offer similar levels of
genome coverage [4,5].
The completeness with which variation is captured must
also be evaluated for different populations. Unfortu-
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nately, the ethnicities of many patients sampled for com-
plex disease gene identification projects will not be
sufficiently reflected in the reference populations (CEU,
YRI, CHB and JPT) selected by the International HapMap
project. In addition, the number of genotyped individuals
in HapMap populations is quite small, leading to under-
representation of SNPs with lower allele frequencies.
Some commercial panels have been designed using the
limited data from HapMap. In this study, we have evalu-
ated the performance of these commercial panels on Hap-
Map populations and on one non-HapMap sample
containing a large number of Estonian individuals. Esto-
nia is a Northern European country that has been influ-
enced by many waves of migration from Europe and
Russia [7].
Several studies have already been performed to evaluate
how well other Caucasian population samples can be
described by tagSNPs calculated from HapMap CEPH
data [7-10]. The authors of one study found that in three
out of four selected gene regions, the tagSNPs of the CEPH
population worked well on other European populations
(> 70% markers had a r2 ≥ 0.8 with one of the CEPH tag-
SNPs) [8]. Another study found that 90–95% of Estonian
SNPs with MAF > 5% have a r2 of at least 0.8 with one of
the CEPH tagSNPs [7]. In a third study, the authors sug-
gest that CEPH samples provide an adequate basis for tag-
SNP selection in Finnish individuals [9]. The study by
Gonzalez-Neira et al. [10] indicates that tagSNPs defined
in Europeans are also efficient for describing Middle East-
ern and Central/South Asian populations. Algorithms for
tagging SNPs in multiple populations have been proposed
by Howie et al. [11].
In view of this information, the aim of our study is to
determine how well the recent commercial genome-wide
genotyping arrays capture genetic variation in reference
HapMap populations and in one non-HapMap popula-
tion.
Results
The number of SNPs in the regions studied
One of our main aims was to compare the tagging per-
formances of different commercial platforms on a non-
HapMap population, specifically an Estonian population.
As the Estonian individuals were genotyped only in two
genomic regions we had to limit the analysis to these
regions. The Estonian genotypes in our study originated
from one gene-rich and one gene-poor ENCODE region
(ENCODE regions of Chromosome 2: ENr112 on 2p16.3
and ENr131 on 2p37.1). In these regions, Yoruban, Asian
and CEPH population samples contained 4540, 4495 and
4670 genotyped SNP assays, respectively (Table 1), in the
final HapMap version 21. The number of genotyped SNPs
in the Estonian population sample was 1420 (Table 2).
These SNPs were randomly selected from the HapMap
Phase I dataset. Among the CEPH, Asian and Estonian
population samples the percentage of markers passing
validation criteria was similar (49%, 48% and 54% for
MAF ≥ 1%), but it was higher in the Yoruban population
sample (68%), possibly because of the higher allelic diver-
sity in African populations. Most of the SNPs that failed
validation did so because of the low frequency of the
minor allele (MAF < 1%).
Evaluating the performance of commercial marker sets in 
capturing the genetic variation of HapMap population 
samples
After selecting and validating SNPs, we compared the per-
formances of commercial panels in two selected regions
with those shown in other publications [4-6]. The com-
parison also gave us information about the performance
of HumanHap 550 on HapMap populations that has not
previously been published.
To evaluate performance of commercial panels, for each
marker present in HapMap data we calculated the best tag-
ging SNP from each commercial panel. Then (a) the per-
centage of SNPs covered with r2 ≥ 0.8, and (b) the mean r2
between each marker and their best tagging SNP for the
investigated population was calculated. This was done for
all population samples with two minor allele frequency
cut-offs (1% and 5%). As shown in Figure 1 A–B, all com-
mercial whole-genome SNP sets have poor coverage on
the Yoruban population, whereas coverage of the CEPH
and Asian populations can reach 80–90% on HumanHap
550. In addition to coverage in two ENCODE regions, the
whole-genome coverage for commercial SNP panels was
Table 1: The number of SNPs used for calculations in each 
HapMap population sample
YRI CEU ASI
All genotyped SNPs in regions 4540 4670 4495
Post validation markers:
MAF = 1%




minGeno = 95% 2438 1912 1991
hwCutoff = 0.001
The number of SNPs genotyped and the numbers of SNPs that passed 
validation criteria are shown. YRI, CEU and ASI (CHB + JPT) are, 
respectively, the Yoruban, CEPH and Asian (Chinese and Japanese) 
population samples from the HapMap data for two ENCODE regions 
of chromosome 2. MAF – minor allele frequency; minGeno – 
percentage of SNPs genotyped; hwCutoff – the p-value of the 
hypothesis that the current SNP is not in the Hardy-Weinberg 
Equilibrium.BMC Genomics 2007, 8:159 http://www.biomedcentral.com/1471-2164/8/159
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also evaluated as in the study by Barrett et al. 2006 [4]. The
previously unpublished HumanHap 550 had the follow-
ing whole-genome coverage estimations: CEU 86%, JTP +
CHB 83%, YRI 48%. Among the technologies analyzed in
this paper, HumanHap 550 had the best performance in
all populations (Table 2). The advantage over HumanHap
300 is that HumanHap 550 has increased coverage in
non-European populations. For other platforms, we
observed coverage values nearly identical to previously
published results (Table 3) despite some differences in
data (HapMap ver.20 combined with Affymetrix geno-
types on the HapMap samples vs. HapMap ver.21). The
mean r2 of the whole genome is shown on Table 3, the
mean r2 of two ENCODE regions is shown in Figure 1 C–
D. In the Table 3, the r2 value expresses the mean r2 of all
SNPs studied and additionally the r2of "covered" SNPs as
in some previous studies [4]. Here again, HumanHap 550
shows higher values than other platforms, although the
increase over HumanHap 300 is not large on the CEPH
population.
Evaluating the performance of commercial marker sets in 
capturing the genetic variation in Estonian population 
samples
Since fewer SNPs were genotyped in the Estonian sample
than in the HapMap populations, the mean r2 and cover-
age of the CEPH, Asian and Yoruban population samples
could not be compared directly with the Estonian one.
Many tagSNPs from the commercial panels were not gen-
otyped in the Estonian sample so their pairwise LD could
not be calculated for the Estonian markers. Our solution
was to reduce the marker counts in the CEPH, Asian and
Yoruban samples so that only the markers present in the
Estonian dataset were used for pairwise LD calculation. By
this means we could calculate the relative performances of
the commercial platforms on the reduced SNP set (vali-
dated markers out of a total of 1420 genotyped in the
Estonian population sample, see Table 2). The calculation
was carried out for the CEPH, Asian, Yoruban and Esto-
nian population samples and the results were expressed as
fractions of the coverage of the CEPH sample (Figure 2A–
D). The results show that the commercial products cover
the SNPs investigated with the same efficiency in the Esto-
nian, Asian and CEPH samples, but tagging performance
was lower in the Yoruban sample.
The fractions of universal and population-specific SNPs in 
commercial panels
It would be interesting to know how universal are the
commercial panels for studying different populations. We
counted the tagSNPs used for describing only one popula-
tion and those that could identify SNPs from multiple
populations (Figure 3 A–B). For each SNP in each popula-
tion sample, the best-describing tagSNP from each of the
commercial panels was identified. We then determined
whether each commercial SNP was the best describer of all
SNPs in one, two or all three populations.
Thus we were able to compare the universality of coverage
of the different commercial platforms in different popula-
tions. We observed a strong bias towards CEPH-specific
markers in the HumanHap 300 panel. This can easily be
explained in terms of the SNP selection strategy used:
markers were picked according to the CEPH HapMap
population data using the r2 based method [12], ensuring
that the CEPH population has best coverage and thus con-
tains more CEPH-specific SNPs. In contrast, GeneChip
100 K and GeneChip 500 K describe population-specific
markers from all three populations fairly equally.
Our results show that universal markers constitute 63–
82% of all SNPs and these numbers are similar in all the
commercial platforms studied. Approximately 10% of the
SNPs in commercial panels describe SNPs from only a sin-
gle population sample.
Discussion
In this study, two 500 kb ENCODE regions (0.3% of the
genome) were used to find the efficiency with which a
non-reference Caucasian population can be tagged by
commercial SNP panels. As the whole-genome SNP cover-
age and the coverage of these two ENCODE regions are
similar, we presume that these ENCODE regions are rep-
resentative samples of the human genome. Estonian gen-
otype data contain fewer commercial panel SNPs. Thus,
several commercial panel SNPs were not genotyped and
Table 2: The reduced number of SNPs used for calculations 
shown in Figure 2
YRI CEU ASI EST
All genotyped SNPs in regions 1406 1407 1407 1420








The number of SNPs genotyped and the numbers of SNPs that passed 
validation criteria are shown. YRI, CEU and ASI (CHB + JPT) are, 
respectively, the Yoruban, CEPH and Asian (Chinese and Japanese) 
population samples from the HapMap data for two ENCODE regions 
of chromosome 2. EST is the Estonian sample data from the same 
region. Counts for the YRI, CEU and ASI population samples show the 
counts of markers that were also genotyped in the Estonian 
population subset (1420 markers in total) and passed validation 
criteria. MAF – minor allele frequency; minGeno – percentage of SNPs 
genotyped; hwCutoff – the p-value of the hypothesis that the current 
SNP is not in the Hardy-Weinberg Equilibrium.BMC Genomics 2007, 8:159 http://www.biomedcentral.com/1471-2164/8/159
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Table 3: Genomic coverage, mean r2between tagged SNPs and their tagSNPs (calculated as in the study by Barrett et al. 2006 [4]) and 
mean r2of all SNPs and their tagSNPs. Common SNPs with MAF ≥ 0.05 were evaluated using Phase II HapMap (v. 21) data
CEU JPT + CHB YRI
coverage (%) mean r2 
tagged SNPs
all SNPs coverage (%) mean r2 
tagged SNPs
all SNPs coverage (%) SNPs all SNPs
Illumina HumanHap 300 76 0.96 0.87 64 0.96 0.81 28 0.96 0.57
Illumina HumanHap 550 86 0.97 0.93 83 0.97 0.91 48 0.96 0.73
Affymetrix GeneChip 100 k 32 0.96 0.54 33 0.96 0.53 15 0.96 0.37
Affymetrix GeneChip 500 k 64 0.98 0.82 66 0.97 0.83 40 0.97 0.68
The performance of first-generation SNP panels on HapMap CEU, YRI and ASI population samples Figure 1
The performance of first-generation SNP panels on HapMap CEU, YRI and ASI population samples. The percentage of markers 
covered (A,B) and the mean r2 between all SNPs and their best tagSNPs from each commercial panel (C,D) of CEPH, Yoruban 
and Asian HapMap population samples in two ENCODE regions (Chromosome 2: ENr112 on 2p16.3 and ENr131 on 2p37.1). 
To correct for the overestimate of coverage, we used the same correction as described by Barrett et al. 2006 [4].
AB
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the LD between them and Estonian genotype data SNP
could not be calculated. The lower density of commercial
panel SNPs might reduce both coverage and mean r2 val-
ues. To overcome the problem, similar HapMap reduced
datasets were created and Estonian set was compared as a
ratio vs. the CEU population results in Figure 2.
The results of our analysis show that the non-reference
Caucasian population is tagged with the same efficiency
as the CEPH population from HapMap. All non-African
populations show similar levels of coverage in all com-
mercial panels, irrespective of the SNP selection method
for each platform. This is consistent with previous studies,
which have shown that the CEPH population data from
HapMap samples can successfully be used to tag other
European population samples [7-10]. Other studies indi-
cate that most of the common SNPs are captured by first-
generation whole genome SNP panels [4,5]. Our study
supports the combination of these results with another
conclusion: commercial SNP panels can capture most of
the common SNPs from non-reference European popula-
tion samples. The new Illumina HumanHap 550
describes common markers slightly better than the
smaller HumanHap 300 platform and reaches 86% cover-
age. Unfortunately, the remaining 14% of markers that
are covered by r2 < 0.8 can be quite numerous. If we
assume that we would like to cover circa 7.5 million mark-
ers overall, 14% gives approximately one million poorly-
Evaluation of the performance of first-generation SNP panels in capturing common variance among the Yoruban, Asian and  Estonian population samples compared to the CEPH population sample Figure 2
Evaluation of the performance of first-generation SNP panels in capturing common variance among the Yoruban, Asian and 
Estonian population samples compared to the CEPH population sample. The relative ratio of markers covered (A,B) and the 
relative ratio of mean r2 between markers and their best tagSNPs (C,D) for the CEPH, Asian, Yoruban and Estonian population 
samples in two ENCODE regions (Chromosome 2: ENr112 on 2p16.3 and ENr131 on 2p37.1). Only markers present in the 
Estonian population sample were used to measure the percentage of markers covered and the mean r2 between markers and 
their best tagSNPs. The results are expressed relative to the CEPH population sample.
A B
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covered markers. Any of these could be the disease-caus-
ing SNP that we are looking for in whole-genome associ-
ation studies. Our hope is that upcoming commercial
platforms will be able to cover most of these currently
uncovered SNPs by additional tagSNPs.
In contrast to the results of previous studies [4,5], we
observed equal or slightly smaller coverage in Asian and
YRI population samples for Affymetrix 500 k than for Illu-
mina HumanHap 300. However, this lower coverage may
be due to the random variation of genomic regions; we
used two 500 kb regions from the whole human genome.
Some commercial panel SNPs can be used to tag markers
from different populations. Other markers, however, are
only useful for describing markers from a single popula-
tion. The information about the universality of tagSNPs is
important for planning association studies in non-Hap-
Map populations. The markers that are able to tag differ-
ent populations are expected to be useful in many
populations. The fraction of universal markers (MAF >
1%) was found to be 72–82%.
Conclusion
We found that in a non-reference Caucasian population,
commercial SNP panels offered similar levels of coverage
to the HapMap CEPH population sample. Although the
coverage of commercial SNP panels has been evaluated
for the HapMap CEPH population sample in previous
papers, our results indicate that it is also possible to use
that information for other European populations. We
present the performance calculations for HumanHap 550,
which have not previously been published. The coverage
of HumanHap 550 reaches 90% of CEPH markers and
45% of Yoruban markers. We also present an analysis of
the fraction of markers on commercial platforms that is
universal and the fraction that is population-specific.
Methods
Data
Two previously resequenced 500-kb ENCODE regions on
chromosome 2 (ENCODE 1: ENr112, NCBI Build 34
positions 51633239–52133238 on 2p16.3 and ENCODE
2: ENr131, NCBI Build 34 positions 234778639–
The number of commercial SNPs necessary to describe all SNPs in different populations Figure 3
The number of commercial SNPs necessary to describe all SNPs in different populations. For each SNP in the commercial pan-
els, we determined whether it was a tagSNP (the SNP with highest r2) for any marker in the selected population samples. For 
example, among the 296 SNP in HumanHap 300 with MAF 1% there were 231 (78%) SNPs that described SNP from all popu-
lations in these regions. Only 20 out of 296 (6.8%) were the best for describing the CEPH population and 2 (0.7%) were the 
best for describing only the Yoruban population. The analysis is based only on the two ENCODE regions in which the Estonian 
markers were genotyped.
MAF 1% MAF 5%BMC Genomics 2007, 8:159 http://www.biomedcentral.com/1471-2164/8/159
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235278638 on 2p37.1) were used in this study. These
regions differ in their average recombination rates (0.8
cM/Mbp for ENCODE 1 and 2.1 cM/Mbp for ENCODE 2)
and content of known genes (ENCODE 1 is a gene-poor
region, whereas ENCODE 2 is a gene-rich region).
Overall, there are 2,431 and 2,067 SNPs in ENCODE 1
and ENCODE 2, respectively. These have been success-
fully genotyped in the HapMap project. From the two
500-kb ENCODE regions, 1420 SNPs were randomly
selected and genotyped in 1090 samples from the Esto-
nian Genome Project Foundation at McGill University
and the Genome Quebec Innovation Centre, as part of the
HapMap project, using the Illumina GoldenGate® Assay.
The total number of monomorphic SNPs was set at 100
for each region in all four HapMap populations included
in the selection process. The same genotype data have pre-
viously been used in a study by Montpetit et al. [7].
For population comparisons, additional genotype data
from CEPH (CEU, Utah residents with northern and west-
ern European ancestry), Asian (ASI, Mixed dataset of Jap-
anese from the Tokyo area and Chinese from Beijing) and
Yoruban (YRI, Yoruba people in Ibadan, Nigeria) popula-
tions of HapMap v. 21 were used, containing 4670 and
4540 SNPs respectively in these ENCODE regions.
Marker validation
The markers for all three populations were validated using
the Haploview program [13]. The population samples
had to have genotyping success ≥ 95%, p-level of Hardy-
Weinberg Equilibrium ≥ 0.001. Two minor allele cut-off
levels were used (1% and 5%) to study the difference in
results if markers with low allele frequency were present.
TagSNP sets and evaluation of coverage
Information about the four evaluated commercial
genome-wide genotyping arrays was retrieved from the
manufacturers' websites: for the Infinium HumanHap
300 and HumanHap 550 Array Sets from Illumina, Inc
[14], and for the Affymetrix GeneChip Mapping 100 K
and the Mapping 500 K Array Sets from Affymetrix, Inc
[15]. For analyzing the two ENCODE regions in HapMap
populations (Figure 1 and 3) the following numbers of
commercial panel SNPs were used: HumanHap 300, 296
SNPs; HumanHap 550,413 SNPs; GeneChip 100 k, 61
SNPs; GeneChip 500 k, 225 SNPs. For analyzing the Esto-
nian dataset together with the reduced HapMap dataset
(Figure 2) the following numbers of commercial panel
SNPs were used: HumanHap 300, 118 SNPs; HumanHap
550,161 SNPs; GeneChip 100 k, 22 SNPs; GeneChip 500
k, 86 SNPs. Marker validation and LD calculations were
performed using the Haploview [13] program.
Coverage numbers shown in Figure 1 and Table 3 were
measured as a fraction of markers that had pairwise r2 > =
0.8 with their best tagSNP from given commercial panel
and its captured SNPs. To correct for the overestimate of
coverage, we used the same correction as described by Bar-
rett et al. 2006 [4].
To analyze how effectively the markers of different tag sets
have been put to use, we determined the counts of tag-
SNPs used to describe each population and tagSNPs that
could tag SNPs from multiple populations.
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